Stock Events

Stock Events

Allakos 

$0.33
39
-$0-0.06% Wednesday 19:59

Statistics

Day High
0.33
Day Low
0.33
52W High
1.56
52W Low
0.22
Volume
724,800
Avg. Volume
1,145,449
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

6AugExpected
Q4 2023
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
-0.81
-0.54
-0.27
0
Expected EPS
-0.19
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-115.82MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALLK. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes in the biotech space, focusing on treatments that could overlap with Allakos' therapeutic areas, including inflammatory diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is involved in creating treatments for autoimmune diseases and other chronic conditions, potentially competing with Allakos' drug development focus.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences operates in the biopharmaceutical field, developing drugs that could compete with Allakos' portfolio, especially in areas like immunology.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has a broad range of biopharmaceutical products that target similar therapeutic areas as Allakos, including autoimmune and inflammatory diseases.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics, with products that could compete in the same markets as Allakos, particularly in inflammation and autoimmunity.
Biogen
BIIB
Mkt Cap22.63B
Biogen's focus on advanced therapies for treating autoimmune disorders places it in direct competition with Allakos' research and development efforts.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca, with its wide range of treatments for various diseases, including those related to inflammation and autoimmunity, competes in similar therapeutic areas as Allakos.
Novartis
NVS
Mkt Cap237.61B
Novartis offers a broad portfolio of healthcare products, including treatments for autoimmune diseases, directly competing with Allakos' therapeutic targets.
Sanofi
SNY
Mkt Cap124.45B
Sanofi operates globally in the pharmaceutical sector, with a focus on treatments for chronic diseases, including those in Allakos' interest areas.
Pfizer
PFE
Mkt Cap140.15B
Pfizer's extensive research and development in biopharmaceuticals, including drugs for inflammatory and autoimmune diseases, makes it a competitor to Allakos.

About

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
Show more...
CEO
Dr. Robert Alexander Ph.D.
Employees
131
Country
US
ISIN
US01671P1003

Listings

0 Comments

Share your thoughts

FAQ

What is Allakos stock price today?▼
The current price of ALLK is $0.33 USD — it has decreased by -0.06% in the past 24 hours. Watch Allakos stock price performance more closely on the chart.
What is Allakos stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Allakos stocks are traded under the ticker ALLK.
Is Allakos stock price growing?▼
ALLK stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Allakos has showed a +2.84% increase.
What is Allakos revenue for the last year?▼
Allakos revenue for the last year amounts to 0 USD.
What is Allakos net income for the last year?▼
ALLK net income for the last year is -115.82M USD.
How many employees does Allakos have?▼
As of April 03, 2026, the company has 131 employees.
In which sector is Allakos located?▼
Allakos operates in the Health Care sector.
When did Allakos complete a stock split?▼
Allakos has not had any recent stock splits.
Where is Allakos headquartered?▼
Allakos is headquartered in San Carlos, US.